An open label, phase Ib rollover study to assess the long-term safety profile of lapatinib (GW572016) in cancer patients.

Trial Profile

An open label, phase Ib rollover study to assess the long-term safety profile of lapatinib (GW572016) in cancer patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 Mar 2010 Additional trial locations (Canada, Israel) identified as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top